TREVENTIS Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TREVENTIS Corporation - overview
Established
2008
Location
-, PA, US
Primary Industry
Biotechnology
About
TREVENTIS Corporation focuses on developing pharmaceutical compounds that address misfolded proteins, which are linked to neurodegenerative diseases. Their proprietary technology aids in designing targeted therapies for conditions like Alzheimer's disease and oncology. TREVENTIS Corporation was founded in 2008 in the US and specializes in the creation of pharmaceutical solutions for neurodegenerative diseases. The company was established by Christopher Barden, Donald Weaver, L.
McIntosh, and William Wong. The company has closed a total of two deals, with the most recent occurring on September 18, 2013, when TREVENTIS secured a GRANT of USD 4. 4 mn from Wellcome Trust. The total amount raised by the company is USD 0.
55 mn. TREVENTIS Corporation specializes in designing and developing pharmaceutical compounds that target misfolded proteins, a significant factor in neurodegenerative diseases. Their proprietary Common Conformational Morphology (CCM) technology is essential for identifying druggable active sites in these proteins, allowing the rational design of small molecules aimed at treating conditions like Alzheimer's disease. TREVENTIS has established partnerships, notably with Takeda, to advance its lead program currently under development, targeting pharmaceutical companies and research institutions in North America and Europe engaged in neurodegenerative diseases and oncology.
TREVENTIS Corporation generates revenue through strategic partnerships, particularly with prominent pharmaceutical companies such as Takeda. The business model includes revenue-sharing agreements, licensing deals for their CCM technology, and joint development programs designed to facilitate the commercialization of their drug candidates, with payments structured around milestones in drug development, research, clinical trials, and regulatory approvals. In September 2013, TREVENTIS Corporation received USD 4. 4 mn from Wellcome Trust, aimed at supporting the advancement of their drug development initiatives.
Future growth plans involve designing and launching new pharmaceutical products targeting misfolded proteins and expanding market presence in North America and Europe by targeting pharmaceutical companies and research institutions. These efforts are supported by recent funding aimed at accelerating the development of therapies in neurodegenerative diseases and oncology.
Current Investors
Wellcome Trust, BioAdvance
Primary Industry
Biotechnology
Sub Industries
Drug Stores/Convenience Stores, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.treventis.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
TREVENTIS Corporation - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.